Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
daunorubicin and cytarabine (CSPC Zhongnuo Pharmaceutical)
- Development stage
- Phase 4
- Lead developer
- CSPC Zhongnuo Pharmaceutical
- Modality
- Small Molecules, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
Daunorubicin and cytarabine liposome (CPX-351) is a liposomal encapsulation of the anthracycline daunorubicin and the antimetabolite cytarabine in a fixed 1:5 molar ratio. This formulation is designed to optimize the synergistic delivery of the two drugs to leukemia cells while reducing systemic toxicity. It is primarily used for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC). CSPC Zhongnuo Pharmaceutical is developing a generic version of this liposomal formulation, which is currently undergoing bioequivalence studies to demonstrate parity with the reference drug, Vyxeos.
- Brand names
- Vyxeos
- Other names
- daunorubicin cytarabine liposomeliposomal daunorubicin and cytarabinedaunorubicin + cytarabine liposome
02
Targets
CDA (Cytidine deaminase)DNATOP2B (DNA topoisomerase II beta)DCK (Deoxycytidine kinase)RNR (Ribonucleotide reductase)DNA polymerase familyTOP2A (DNA topoisomerase II)
Beyond the preview
Go deeper on daunorubicin and cytarabine (CSPC Zhongnuo Pharmaceutical).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on daunorubicin and cytarabine (CSPC Zhongnuo Pharmaceutical).